Clinical Updates**

One in ten Americans, approximately 35 million people, have peripheral neuropathy (PN).  This is an epidemic by any definition.  Over the past decades the incidence of PN has grown dramatically as it [CLICK TO READ MORE]

A recently published paper in the journal Diabetes Therapy, examines the impact of alcohol use in diabetic patients with distal symmetrical polyneuropathy (DSP).  In the [CLICK TO READ MORE]

Summary: Benfotiamine and alpha lipoic acid (ALA) are two of the most commonly used nutrients in the treatment of peripheral neuropathy.  Although both may be beneficial, ALA is associated [CLICK TO READ MORE]

In order for neurons to successfully perform their primary function of conducting action potentials, their mitochondria produce significantly greater amounts of energy, in the form of ATP, than all [CLICK TO READ MORE]

Summary: Recent studies indicate that type 2 diabetics with peripheral neuropathy are at increased risk of undergoing cognitive decline and earlier mortality than type 2 diabetics who do not have [CLICK TO READ MORE]

  A group of investigators from the UK recently performed an extensive review of the scientific literature in an attempt to better determine the prevalence of peripheral neuropathy in patients [CLICK TO READ MORE]

  Summary: In a ground-breaking study, investigators found that decreased sensation in the foot may be an underrecognized risk factor for death.  Mortality among adults with nondiabetic [CLICK TO READ MORE]

This phase II multi-institutional study was the largest to date to look at the therapeutic benefits of using benfotiamine in patients suffering from AZ.  It followed, over a 12-month period, a cohort [CLICK TO READ MORE]

Summary:  Obstructive sleep apnea (OSA) is a common, independent, and often-overlooked cause of peripheral neuropathy.  Additionally, in type 2 diabetics, OSA has been shown to significantly increase [CLICK TO READ MORE]

On April 17, 2020, the online New England Journal of Medicine published the correspondence Guillain-Barré Syndrome Associated with SARS-CoV-2.  The paper was authored by a team of Italian physicians [CLICK TO READ MORE]

At present, there is no reason to believe that COVID-19 is responsible for any sensory defects of the lower extremity.  In fact, The Foundation for Peripheral Neuropathy, a reputable patient advocacy [CLICK TO READ MORE]

Polyneuropathy, the most common form of peripheral neuropathy, is a condition in which neurons of the peripheral nervous system dysfunction progressively, over time, in a length dependent manner-the [CLICK TO READ MORE]

During episodes of hyperglycemia, unlike most other cell types, the neurons and Schwann cells of the peripheral nervous system are unable to successfully prevent the rise of their internal glucose [CLICK TO READ MORE]

With estimates of the incidence of prediabetes in the USA at over 84 million people, prediabetes is an epidemic by any definition.  It is also one of the leading causes of peripheral neuropathy with [CLICK TO READ MORE]

Summary: The association between peripheral neuropathy and prediabetes, although not well known by clinicians, is well established in the scientific literature. It is estimated that up to 15 million [CLICK TO READ MORE]

In 2015, according to The National Institutes of Health (NIH), there were approximately 15 million alcoholics in the US-with estimates suggesting that up to 10 million of them suffered from painful [CLICK TO READ MORE]

Summary:  Research group finds that type 2 diabetics with foot ulcers possess fewer cognitive resources than a matched group of type 2 diabetics without foot ulcers. There is a well-established [CLICK TO READ MORE]

If you are one of the thousands of physicians who use benfotiamine, a high potency lipid-soluble form of thiamine (vitamin B1), in the treatment of polyneuropathy, you are certainly aware of its [CLICK TO READ MORE]

Dr. Richard H Mann, DABPS, ret Chief Scientific Officer & Founder, Realm Labs, Makers of Nutrients to Improve the Function of the Nerves in the Feet and Legs. Which one of the following [CLICK TO READ MORE]

Clinician Alert: Reversing Thiamine (Vitamin B1) Deficiency in the Treatment of Diabetic Polyneuropathy: An Important Therapeutic Goal by Dr. Richard H Mann, DABPS, ret Chief Scientific Officer & [CLICK TO READ MORE]

Clinician Alert: Patients Successfully Treated with Benfotiamine for Alcoholic Polyneuropathy May Also Experience Improved Cognitive Function Thiamine (Vitamin B1) deficiency is a well-known and [CLICK TO READ MORE]

Is Prediabetes a Risk Factor for Neuropathy? According to the American Diabetes Association, before people develop type 2 diabetes, they almost always have “prediabetes” – blood [CLICK TO READ MORE]